This was shown to increase the sensitivity of cancer cells to conventional anti-cancer agents, especially, malignant cells harboring mutant forms of EGFR, which are often dependent on HSP90 for their stability (Lee et al., 2016). Here, HSP90AA1 is linked to cancer.